Natural history of chronic hepatitis C

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 1, 1999, Pages 28-44

  Pagliaro, L ^a   Peri, V ^a   Linea, C ^a   Camma C ^a   Giunta, M ^a   Magrin, S ^a  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

Chronic hepatitis; Hepatitis C virus; Liver cirrhosis

Indexed keywords

ALCOHOL; AMINOTRANSFERASE; IMMUNOGLOBULIN D ANTIBODY; IRON; VIRUS RNA;

AGE; ALCOHOL CONSUMPTION; ARTICLE; BLOOD TRANSFUSION; CHRONIC HEPATITIS; DISEASE COURSE; DISEASE DURATION; ENZYME ACTIVITY; FEMALE; GENDER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE;

ADULT; BIOPSY; CARCINOMA, HEPATOCELLULAR; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; RNA, VIRAL; SURVIVAL RATE;

EID: 0032908398     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (152)

1. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991;14:969-74.
2. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
3. Hopf U, Moller B, Kuther D, Stemerowicz R, Lobeck H, Ludtke-Handjery A, et al. Long-term follow-up of post-transfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990;10:69-76.
4. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992;15:948-63.
5. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801.
6. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber SL et al. Long-term mortality after transfusion associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-11.
7. Mulrow CD. The medical review article: state of the science. Ann Intern Med 1987;106:485-91.
8. Eddy MD, Hasselblad V, Shacter R. An introduction to a bayesian method for meta-analysis: the confidence profile method. Med Decis Making 1990;10:15-23.
9. Eddy MD, Hasselblad V, Shacter R. Meta-analysis by the confidence profile method. The statistical synthesis of evidence. Appendix B. Fast*Pro demo: a demonstration of the confidence profile method with an attached disk. Boston: Academic Press; 1992. p. 371-419.
10. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis - looking back in the second decade. Ann Intern Med 1993;119:110-5.
11. Crowe J, Doyle C, Fielding JF, Holloway H, Keegan M, Kelleher D, et al. Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation. Gastroenterology 1995;108:A1054.
12. Wiese M. Natural course of hepatitis C: a 15 year analysis in an unselected group with an identical parenteral infection. J Hepatol 1995;23 (Suppl 1):89.
13. Muller R. The natural history of hepatitis C: clinical experiences. J Hepatol 1996;24(Suppl.2):52-4.
14. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander J, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
15. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long-term prognosis of hepatits C virus infection in Japan. Gut 1993;34(Suppl.):S13-6.
16. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, et al. Persistent hepatitis C viremia after acute self-limiting post-transfusion hepatitis C. Hepatology 1995;21:639-44.
17. Lampertico P, Rumi M, Romeo R, Craxì A, Soffredini R, Biassoni D, et al. A multicenter randomized controlled trial of recombinant interferon-α2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
18. Viladomiu L, Genescà J, Esteban JI, Allende H, Gonzales A, Lopez-Talavera JC, et al. Interferon-α in acute post-transfusion hepatitis C: a randomized, controlled trial. Hepatology 1992;15:767-9.
19. Hwang SJ, Lee SD, Chan CH, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon α-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994:21:831-6.
20. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338:914-5.
21. Ohnishi K, Nomura F, Nakano M. Interferon therapy for acute posttransfusion non-A, non-B hepatitis: response with respect to antihepatitis C virus antibody status. Am J Gastroenterol 1991;86:1041-9.
22. Tassopoulos NC, Koutelou MG, Papatheodoridis G, Polychronaki H, Delladetsima I, Giannikakis T, et al. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis. Gut 1993;34(Suppl.):S130-2.
23. Alberti A, Belussi F, Chemello L, Benvegnù L, Pontisso P. Outcome of acute hepatitis C and role of interferon alpha (IFN-2a) therapy. Proceedings of the International Symposium on Viral Hepatitis and Liver Disease. Tokyo; 1993. p. 10-4.
24. Palmovich D, Kurelac J, Crnjakovic-Palmovich J. The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha. Infection 1994;22:222-3.
25. Seeff and The NHBLI Study Group. Mortality and morbidity of . transfusion associated type C hepatitis: an NHLBI multi-center study. Hepatology 1994;20:A204.
26. Castells L, Vargas V, Gonzales A, Esteban R, Guardia J. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 1995;15:159-63.
27. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
28. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993;88:240-3.
29. Tong MJ, El-Farra NS, Reikes AR, Co RJ. Clinical outcomes after transfusion associated hepatitis C. N Engl J Med 1995;332:1463-6.
30. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC Groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
31. Roberts JM, Searle YW, Cooksley WG. Histological patterns of prolonged hepatitis C infection. Gastroenterol Jpn 1993;28(Suppl.5):37-41.
32. Watson JP, Brind AM, Chapman CE, Bates CL, Gould FK, Johnson SJ, et al. Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut 1996;38:269-76.
33. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6.664 patients. The Study Group for the Prevalence and Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-90
34. Kao JH, Tsai SL, Chen PJ, Yang PM, Sheu JC, Lai MY, et al. A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. J Hepatol 1994;21:244-9.
35. Sanchez-Tapias JM, Lo lacono O. Storia naturale dell'infezione cronica da HCV: dall'epatite cronica alla cirrosi. In Craxì A, Almasio P, Magrin S, editors. II virus dell'epatite C (HCV): l'infezione e la malattia. Vol. 2. Milano: Roche; 1995. p. 11-25.
36. Mattson L, Sonnenborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993;13:274-8.
37. Wejstal R, Hermodsson S, Norkrans G. Long-term follow-up of chronic hepatitis non-A, non-B - with special reference to hepatitis C. Liver 1991;11:143-8.
38. Yousuf M, Nakano Y, Tanaka E, Sodeyama T, Kiyosawa K. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol 1992;27:812-6.
39. Vaquer P, Canet R, Llompart A, Riera J, Obrador A, Gayà J. Histological evolution of chronic hepatits C. Factors related to progression. Liver 1994;14:265-9.
40. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996;23:695-9.
41. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inowe O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
42. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-5.
43. Shev S, Dhillon AP, Lindh M, Serléus Z, Wejstal R, Widell A, et al. The importance of cofactors in the histological progression of minimal and mild chronic hepatitis C. Liver 1997;17:215-23.
44. Mattson L, Weiland O, Glaumann H. Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up - a comparison. Liver 1989;9:120-7.
45. Snedecor GW, Cochran WG. Statistical methods. Ames, The Iowa State University Press, 7th Ed; 1980. p. 191-3.
46. Layde PM, Broste SK, Desbiens N, Follen M, Lynn J, Reding D, et al. Generalizability of clinical studies conducted at tertiary care medical centers: a population-based analysis. J Clin Epidemiol 1996;49:835-41.
47. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992;15:567-71.
48. Bedossa P, Poynard T for the METAVIR Cooperative Study Group. An algorithm for the grading activity in chronic hepatitis C. Hepatology 1996;24:289-93.
49. Delladetsima JK, Rassidakis G, Tassopoulos NC, Papatheodoridis GV, Smyrnoff T, Vafiadis I. Histopathology of chronic hepatits C in relation to epidemiological factors. J Hepatol 1996;24:27-32.
50. Colombari R, Dhillon AP, Piazzola E, Tomezzoli AA, Angelini GP, Capra F, et al. Chronic hepatitis in multiple virus infection: histopathological evaluation. Histopathology 1993;22:319-25.
51. Serfaty L Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of response to Interferon in patients with chronic hepatitis C. J Hepatol 1994;21:12-7.
52. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995;123:330-7.
53. Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, et al. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 1995;22:457-63.
54. Donato MF, Ronchi G, Callea F, Iba M, Morcelli R, Del Ninno E, et al. Long-term follow-up of anti-HCV positive patients with chronic persistent hepatitis (CPH-C). Ital J Gastroenterol 1993;25(Suppl.l):S32.
55. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JN, Garcia G, et al. Survival in chronic hepatitis B. Ann Intern Med 1984;101:613-6.
56. Wright EC, Seef LB, Berk PD, Jones EA, Plotz PH. Treatment of chronic active hepatitis. Gastroenterology 1977;73:1422-30.
57. Bianchi L, De Groote J, Desmet VJ, Gedigk P, Korb G, Popper H. Acute and chronic hepatitis revisited. Review by an International Group. Lancet 1977;ii:914-9.
58. Cooksley WGE, Bradbear RA, Robinson W, Harrison M, Halliday JW, Powell LW, et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986;6:345-8.
59. Combes B. The initial morphologic lesion in chronic hepatitis, important or unimportant? Hepatology 1986;6:518-22.
60. Boyer JL. Chronic hepatitis. A perspective on classification and determinants of prognosis. Gastroenterology 1976;70:1161-71.
61. McIntyre N, Rosalki S. Biochemical investigations in the management of liver disease. In McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J editors. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1991:293-309.
62. Healey CJ, Chapman RWG, Fleming KA. Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. Gut 1995;37:274-8.
63. Cahen DL, Van Leeuwen DJ, Ten Kate FJW, Blok APR, Costing J, Chamuleau RAFM. Do serum ALAT values reflect the inflammatory activity in the liver of patients with chronic viral hepatitis? Liver 1996;16:105-9.
64. Bronkhorst CM, Brouwer JT, Nevens F, Elewault A, Adler M, Brenard R, et al. Pretreatment histology in 288 patients in the Benelux with chronic hepatitis C: correlation with clinical parameters and prediction of response to interferon. Hepatology 1995;22:A275.
65. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopatological manifestation of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997;25;735-9
66. Alberti A, Chemello L, Cavalletti D, Tagger A, Dal Canton A, Bizzarro N, et al. Antibody to hepatitis C virus and liver disease in volunteer blood donors. Ann Intern Med 1991;114:1010-2.
67. Bruno S, Rossi S, Petroni ML, Villa E, Zuin M, Podda M. Normal aminotransferase concentrations in patients with antibodies to hepatitis C virus. Br Med J 1994;308:697.
68. Conry-Cantilena C, VanRaden M, Gibble J, Melpoder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
69. Esteban JI, Lòpez-Talavera JC, Genescà J, Madoz P, Viladomiu L, Muniz E, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-9.
70. Gholson CF, Morgan K, Catinis G, Favrot D, Taylor B, Gonzales E, et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 1997;92:1788-92.
71. Kodama T, Tamaki T, Katabami S, Katamuma A, Yamashita K, Azuma N, et al. Histological findings in asymptomatic hepatitis C virus carriers. J Gastroenterol Hepatol 1993;8:403-5.
72. Kolho E, Farkkila M, Makinen J, Krusius T, Naukkarinen R, Ikkala E. Clinical significance of hepatitis C antibodies in blood donors. J Med Virol 1994;43:129-34.
73. Morales TG, Sampliner RE, Bhattacharyya A, Alter M. Liver histology in anti-HCV-positive persons with normal or minimally elevated aminotransferases. J Clin Gastroenterol 1995;21:301-5.
74. Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H, et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994;19:871-5.
75. Okanoue T, Yasui K, Sakamoto S, Minami M, Itoh Y, Kagawa K, et al. Circulating HCV-RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study. Liver 1996;16:241-7.
76. Prati D, Capelli C, Zanella A, Mozzi F, Bosoni P, Pappalettera M, et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 1996;110:178-83.
77. Prieto M, Olaso V, Verdù C, Cordoba J, Gisbert C, Rayòn M, et al. Does the healthy hepatitis C carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995;22:413-7.
78. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997;26:1393-8.
79. Serfaty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon R. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test. Hepatology 1995;22:725-9.
80. Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus positive subjects with normal liver biochemical values. Hepatology 1995;22:418-25.
81. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21:285-90.
82. Yuki N, Hayashi N, Kamada T. HCV viraemia and liver injury in symptom free blood donors. Lancet 1993;342:444.
83. Yun ZB, Lindh G, Weiland O, Johansson B, Sonnerborg A. Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors. J Med Virol 1993;39:57-61.
84. Van Thiel DH, Caraceni P, Molloy PJ, Hassanein T, Kania RJ, Gurakar A, et al. Chronic hepatitis C in patients with normal or near-normal alanine aminotransferase levels: the role of interferon α2b therapy. J Hepatol 1995;23:503-8.
85. Hess B. Enzymes in blood plasma. In: Henley KS, editor. Diseases of the liver and biliary duct. New York: Academic Press; 1963. p. 80-98.
86. Mathurin P, Moussali J, Cadranel J-F, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-72.
87. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25:211-5.
88. Booth JCL, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL, et al. Chronic hepatitis C virus infections: predictive value of genotype and level of viremia on disease progression and response to interferon alpha. Gut 1995;36:427-32.
89. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19:13-8.
90. Ichimura H, Tamura I, Kurimura O, Koda T, Mizui M, Tsuchie H, et al. Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease. J Med Virol 1994;43:212-5.
91. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
92. Lee DS, Sung YC, Whang YS. Distribution of HCV genotypes among blood donors, patients with chronic liver disease, hepatocellular carcinoma, and patients on maintenance hemodialysis in Korea. J Med Virol 1996;49:55-60.
93. Lopez-Labrador FX, Ampurdanès S, Forns X, Castells A, Sàiz JC, et al. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol 1997;27:959-65.
94. Magrin S, Craxì A, Fabiano C, Marino L, Fiorentino G, Lo Iacono O, et al. HCV viremia is more important than genotype as predictor of response to interferon in Sicily (Southern Italy). J Hepatol 1996;49:583-90.
95. Mahaney K, Tedeschi V, Mertens G, Di Bisceglie AM, Vergalla J, Hoofnagle J, et al. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994;20:1405-11.
96. Nousbaum JB, Poll S, Nalpas B, Landais P, Berthelot P, Bréchot C, and the Collaborative Study Group. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995;122:161-8.
97. Pistello M, Maggi F, Vatteroni L, Cecconi N, Panicucci F, Bresci GP, et al. Prevalence of hepatitis C virus genotypes in Italy. J Clin Microbiol 1994;32:232-4.
98. Pozzato G, Moretti M, Franzin F, Crocè LS, Tiribelli C, Masayu T, et al. Severity of liver disease with different hepatitis C virus clones. Lancet 1991;338:509.
99. Rugge GM, Thung SN, Chemello L, Leandro G, Alberti A, Cecchetto A, et al. Hepatitis C virus serotypes and liver pathology. Liver 1996;16:353-7.
100. Serfaty L, Chazouilleres O, Poujol-Robert A, Morand-Joubert L, Dubois C, Chretien Y, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology 1997;26:776-9.
101. Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996;111:199-205.
102. Simmonds P, Mellor J, Craxì A, Sanchez-Tapias JM, Alberti A, Prieto J, et al. Epidemiological, clinical and therapeutic association of hepatitis C types in Western European patients. J Hepatol 1996;24:517-24.
103. Romeo R, Colombo M, Rumi M, Soffredini R, Del Ninno E, Donato MF, et al. Lack of association between type of hepatitis C virus, serum load and severity of liver disease. J Viral Hepat 1996;3:183-90.
104. Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, et al. Hepatitis C genotypes are not responsible for development of serious liver disease. Dig Dis Sci 1994;39:234-9.
105. Zein NZ, Rakela J, Krawitt EL, Reddy R, Tominaga T, Persing DH, and the Collaborative Study Group. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996;125:634-9.
106. Brechot C. Hepatitis C virus 1b, cirrhosis and hepatocellular carcinoma. Hepatology 1997;25:772-4.
107. Magrin S, Craxì A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-α or corticosteroid treatment. Hepatology 1994;19:273-9.
108. Fernandez I, Castellano G, Domingo MJ, Fuertes A, Colina F, Canga F, et al. Influence of viral genotype and level of viremia on the severity of liver injury and response to interferon therapy in Spanish patients with chronic hepatitis C infection. Scand J Gastroenterol 1997;32:70-6.
109. Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993;17:545-50.
110. Nakagawa H, Hiroyuki S, Hasui T, Tsuji H, Tsuji T. Quantitative detection of hepatitis C virus genome in liver tissue and circulation by competitive reverse transcription-polymerase chain reaction. Dig Dis Sci 1994;39:225-33.
111. Hu KQ, Yu CH, Vierling JM. Direct detection of circulating hepatitis C virus RNA using probes from the 5′ untranslated region. J Clin Invest 1992;89:2040-5.
112. Kato N, Yosuka H, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993;18:16-20.
113. Giostra F, Francesconi R, Groff P, Manzin A, Solforosi L, Lan F, et al. Wide fluctuation of plasmatic HCV genome levels in serial samples of patients before Interferon (IFN) treatment. J Hepatol 1995;23(S1):105.
114. Hawkings A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV-RNA assay version 1 and 2, Roche monitor assay, and a in-house limiting dilution method. J Clin Microbiol 1997;35:187-92.
115. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
116. Yamada M, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-4.
117. Orito E, Mizokami M, Suzuki K, Ohba KI, Ohno T, Mori M, et al. Loss of serum HCV-RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995;46:109-15.
118. Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon α2a therapy. J Med Virol 1995;46:162-8.
119. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, et al. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-α therapy in chronic hepatitis C patients. J Med Virol 1996;48:354-9.
120. Mizokami M, Onto E, Gibo Y, Suzuki KI, Ohba KI, Ohno T, et al. Genotype, serum level of hepatitis C virus RNA and liver histology as predictor of response to interferon-α 2a therapy in Japanese patients with chronic hepatitis C. Liver 1996;16:23-7.
121. Chan CY, Lee SD, Hwang SJ, Lu RH, Lo KJ. Quantitative branched DNA assay and genotyping for hepatitis C virus RNA in Chinese patients with acute an chronic hepatitis C. J Infect Dis 1995;171:443-6.
122. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon- α2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994;39:1273-80.
123. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994;89:2151-6.
124. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
125. Zeuzem S, Franke A, Lee J, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function test, and histology. Hepatology 1996;24:1003-9.
126. Caldwell SH, Jeffers LJ, Ditomaso A, Millar A, Clark RM, Rabassa A, et al. Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am J Gastroenterol 1991;86:1219-23.
127. Fong TL, Kanel GC, Konrad A, Valinluck B, Charboneau F, Adkinns RH. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994;19:554-7.
128. Halimi C, Deny P, Gotheil C, Trinket JC, Mal F, Scavizzi M, et al. Pathogenesis of liver cirrhosis in alcoholic patients: histological evidence for hepatitis C virus responsibility. Liver 1991;11:329-33.
129. Mendenhall CL, Seeff L, Diehl AM, Ghosn SJ, French SW, Gartside PS, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. Hepatology 1991;14:581-9.
130. Nalpas B, Thiers V, Pol S, Driss F, Thepot V, Berthelot P, et al. Hepatitis C viremia and anti-HCV antibodies in alcoholics. J Hepatol 1992;14:381-4.
131. Nishiguchi S, Kuroki T, Yabusako T, Seki S, Kobayashi K, Monna T, et al. Detection of hepatitis C virus antibodies and hepatitis C virus RNA in patients with alcoholic liver disease. Hepatology 1991;14:985-9.
132. Noguchi O, Yamaoka K, Ikeda T, Tozuka S, Sakamoto S, Kanayama M, et al. Clinicopathological analysis of alcoholic liver disease complicating chronic type C hepatitis. Liver 1991;11:225-30.
133. Pares A, Barrera JM, Caballeria J, Ercilla G, Bruguera M, Caballeria L, Rodés J. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology 1990;12:1295-9.
134. Zarski JP, Thelu MA, Moulin C, Rachail M, Seigneurin JM. Interest of the detection of hepatitis C virus RNA in patients with alcoholic liver disease. Comparison with the HBV status. J Hepatol 1993;17:10-4.
135. Cromie SL, Jenkins PJ, Bawden DS, Dudley FJ. Chronic hepatitis C: effect of alcohol on hepatitic activity and viral titre. J Hepatol 1996;25:821-6.
136. Ohnishi K, Matsuo S, Mtsutani K, Itahashi M, Kakihara K, Suzuki K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996;91:1374-9.
137. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994;29:1039-43.
138. Oshita M, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994;20:1115-20.
139. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurement of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-13.
140. Riggio O, Montagnese F, Fiore P, Folino S, Giambartolomei S, Gandin C, et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol 1997;92:1298-301.
141. Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 1997;41:127-8.
142. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A. Emosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. Hum Pathol 1995;26:1080-5.
143. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996;5:633-8.
144. Haque S, Chandra B, Gerber MA, Lok AS. Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Hum Pathol 1996;27:1277-81.
145. Sartori M, Adorno S, La Terra G, Boldorini R, Leone F, Pittau S, et al. Evaluation of iron status in patients with chronic hepatitis C. Ital J Gastroenterol Hepatol 1998;30:396-401.
146. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997;25:759-68.
147. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, et al. Iron stores, response to alpha-interferon therapy and effect of iron depletion in chronic hepatitis C. Liver 1996;16:248-54.
148. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL. Effect of iron depletion on long term response to interferon alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997;92:1831-4.
149. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferases levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89;986-8.
150. Desai TK. Phlebotomy reduces transaminase levels without inducing iron deficiency in patients with chronic hepatitis C. Hepatology 1995;22:A408.
151. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in Southern Italy. Hepatology 1997;26:1006-11.
152. Stroffolini T, Guadagnino V, Chionne P, Procopio B, Mazzuca EG, Scerbo A. A population based survey of hepatitis B virus in a Southern Italian town. Ital J Gastroenterol Hepatol 1997;29:415-9.